By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Multi User License - $2,800
Coming Soon
AI algorithms that can identify ever-smaller lung tumours have been developed in response to the requirement for early diagnosis. Because of the limitations of human eyesight, radiologists are prone to overlooking small cancerous tumours. For example, up to 35% of lung nodules are overlooked during the first examination.
AI technology can help on both counts by taking part of the load off of overworked professionals and finding lung spots that aren’t evident to the human eye. Computer-assisted diagnostic technologies are already used by radiologists to help them detect malignant tumours.
The Global AI Powered Cancer Diagnostic Market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2027, registering a CAGR of XX% from 2022 to 2027.
Scientists are discovering new methods to use artificial intelligence (AI) in the healthcare area as it keeps expanding. AI has played a key role in the diagnosis, decision-making, and treatment of chronic diseases, particularly in medical research.
AI integration in precision medicine might enhance diagnostic efficiency and accuracy, help healthcare decision, and result in improved healthcare outcomes. Clinical care driven by AI has the potential to significantly reduce health inequities, especially in the low environments.
GE Healthcare a leading mobiliser of the Mobility solutions involving cancer solutions orienting towards AI Cancer requirements in the market. It detects and assesses the likelihood of malignancy in a lung nodule, which is crucial for assessing whether or not a biopsy is required and for speeding up diagnosis.
It’s the first AI-assisted diagnostic programme approved by the FDA for early-stage lung cancer, and it’s been demonstrated to enhance the high sensitivity of undetermined nodular aggressiveness evaluations.
Siemens AG is part of the component manufacture trending companies in the current industry. Its latest addition has been brought in through the AI-Pathway Companion Lung Cancer aids multidimensional teams (MDT) by centralising patient care and case reviews on an unified platform, offering data quality assurance, and allowing for the production of clinically important patient-specific footnotes. This is a waste of time and effort for all MDT participants.
